CDKN2A and ovarian carcinoma: Consistent with our consequences, recent research has also proven the prognostic position of CDKN2A / B in pancreatic, lung, breast, melanoma, and ovarian cancers (Qiu et al., 2015 [23]; Seifi et al., 2019 [25]; Compa et al., 2016 [40]; Schuster et al., 2014 [41]).